GlassScriptPhysician profile
Tarek Bakdash
NPI 1871545921
$4,051.68
in general payments reported to CMS, 2019-2025
37 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $552 · 2021: $241 · 2022: $615 · 2023: $710 · 2024: $722 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $498.10 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $403.31 | 2021-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $309.35 | 2019-2025 | Ultomiris |
| Ucb, INC. | $269.46 | 2019-2025 | Zilbrysq, Briviact |
| Allergan, INC. | $262.44 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $257.37 | 2019-2025 | Austedo, Austedo Xr |
| Neurelis, INC. | $246.28 | 2022-2025 | Valtoco |
| Genentech USA, INC. | $148.38 | 2020-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Biogen, INC. | $145.93 | 2020-2025 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $144.54 | 2023-2025 | |
| Kyowa Kirin, INC. | $135.78 | 2020-2023 | Nourianz |
| Lundbeck LLC | $108.19 | 2019-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceuticals, INC. | $96.83 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $82.90 | 2019-2025 | |
| Sk Life Science, INC. | $76.87 | 2022-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $76.67 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.84 | 2022 | |
| Eisai INC. | $70.22 | 2022-2024 | |
| Mdd US Operations, LLC | $69.76 | 2022 | |
| Amgen INC. | $63.35 | 2019-2022 | |
| Grifols USA, LLC | $49.82 | 2023-2024 | Xembify, Gamunex-C |
| Avanir Pharmaceuticals, INC. | $48.13 | 2022 | |
| Acadia Pharmaceuticals INC | $47.10 | 2019 | |
| Abbvie INC. | $44.97 | 2021-2022 | |
| Argenx US, INC. | $43.43 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Sumitomo Pharma America, INC. | $38.85 | 2023 | Aptiom |
| Genzyme Corporation | $34.61 | 2020-2021 | |
| Tanabe Pharma America, INC. | $31.05 | 2020-2023 | |
| Adamas Pharmaceuticals, INC. | $28.41 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $27.21 | 2025 | Crexont |
| Scilex Pharmaceuticals INC. | $22.68 | 2024 | |
| Livanova USA, INC. | $20.99 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Sanofi-Aventis U.S. LLC | $18.18 | 2020 | |
| Almatica Pharma LLC | $17.53 | 2023 | Gralise |
| Corium, LLC | $14.80 | 2023 | Adlarity |
| Sunovion Pharmaceuticals INC. | $13.03 | 2019 | |
| Csl Behring | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarek Bakdash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.